Skip to main content
CTNMContineum Therapeutics, Inc.Hold5.3·$8.68
HoldModerate Confidence
Investment thesis

Contineum Therapeutics shows meaningful analyst-implied upside and bullish above-200-day-MA momentum, but a quality score far below the engine's floor, modest insider selling, and its binary-outcome biotechnology profile keep the engine's stance at exit.

Thesis pillars

  • Analyst Upside Valuation→Stable
  • Quality Floor Exit Signal↑Improving
  • Overbought Momentum Risk↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 5, 2026· older than 90 days

Full reasoning →

Open full analysis

Contineum Therapeutics, Inc. (CTNM) Stock Analysis

Recovery setup · Inst Constrain edge

HoldVALUE-TRAP 3/5ValueModerate Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $8.68, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $341M below $400M minimum.

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis.... Read more

$8.68+114.8% A.UpsideScore 5.3/10#109 of 240 Biotechnology
QualityF-score4 / 9FCF yield-9.55%
Stop $8.07Analyst target $18.64(−13% haircut)A.R:R 7.7:1
Analyst consensus$21.43+146.9%7 analysts with price targets
$18.64Analyst target
$8.68price
$21.43mean
$30

Hold if already holding. Not a fresh buy at $8.68, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $341M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 42. Market cap $341M below $400M minimum. Not in investable universe. Score 5.3/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 102d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About Contineum Therapeutics, Inc.

About Contineum Therapeutics, Inc.

Contineum Therapeutics' wholly-owned lead asset, PIPE-791, is a brain-penetrant LPA1 receptor antagonist advancing into a Phase 2 trial for idiopathic pulmonary fibrosis that began enrolling roughly 324 subjects in December 2025, alongside a completed Phase 1b trial in chronic pain with data expected in the second quarter of 2026. The clinical-stage biopharmaceutical company partners its second program, PIPE-307, a muscarinic M1 receptor antagonist renamed JNJ-89495120, with Johnson & Johnson, which reported $7.8 billion of neuroscience drug sales in 2025.

PIPE-791 targets the LPA1 receptor pathway implicated in pulmonary fibrosis, a mechanism the company says is clinically validated by third-party trials of other LPA1R antagonists, and Contineum is positioning the drug's once-daily dosing as a tolerability advantage over the three currently approved IPF therapies, which require multiple daily doses. PIPE-307 targets major depressive disorder and relapsing-remitting multiple sclerosis; J&J began its Phase 2 Moonlight-1 trial for MDD in December 2024 and retains sole discretion over whether to continue developing the molecule for either indication. Contineum deferred further clinical development of a separate PIPE-791 progressive multiple sclerosis program and its preclinical CTX-343 program in 2025 pending additional funding, concentrating near-term spending on the IPF and chronic pain indications.

Show full overview

Contineum's two-program structure carries asymmetric risk: PIPE-307's Phase 2 VISTA trial in relapsing-remitting multiple sclerosis, reported in November 2025, showed acceptable safety but missed both its primary and secondary efficacy endpoints, and J&J holds sole discretion over whether PIPE-307 advances further in RRMS, MDD, or any other indication. That leaves wholly-owned PIPE-791 as the more direct driver of company value, with the ongoing 26-week PROPEL-IPF trial measuring forced vital capacity as its primary efficacy endpoint against three already-approved competitors, including a nerandomilast product newly approved for U.S. marketing in 2025.

See also: Healthcare · Biotechnology

From Contineum Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 9, 2026

Recent Developments — Contineum Therapeutics, Inc.

Latest item Nov 9, 2026 · Generated 2026-11-22T11:52:06Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 4, 2027102d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: PIPE-791
Market cap $341M below $400M minimum
Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -5577.0%), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)-4.1
Mkt Cap$341M
EV/EBITDA-1.4
Profit Mgn0.0%
ROE-29.8%
Rev Growth—
Beta1.07
DividendNone
Analysts with ratings14

Quality Signals

Piotroski F4/9

Options Flow

P/C0.11bullish
IV205%elevated

Concentration Risks(10-K Item 1A)

  • HIGHpipelinePIPE-791
    10-K Item 1: 'Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor ("LPA1R") in development for idiopathic pulmonary fibrosis ("IPF") and chronic pain.'
  • MEDIUMcounterpartyJohnson & Johnson (PIPE-307 partner)
    10-K Item 1: 'J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Volume
2.8
Rsi
4.5
Macd
6.4
Volume distribution (falling OBV)Below 200-MA, MA slope -3.4%/30d — confirmed downtrend

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
2.9
Earnings History
3.3
Erm
3.5
Earnings Timing
5.0
Earnings concerns: 2B/2M
GatesMomentum 3.1<4.5Death cross (50MA < 200MA)A.R:R 7.7 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 102d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Speculative
RSI
42 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $8.02Resistance $10.90

Price Targets

$8
$19
A.Upside+114.8%
A.R:R7.7:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Market cap $341M below $400M minimum
! Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -5577.0%), Negative free cash flow
! momentum at 3.1 (below the engine's 4.5 threshold)

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-03-04 (102d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CTNM stock a buy right now?

Hold if already holding. Not a fresh buy at $8.68, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $341M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 42. Market cap $341M below $400M minimum. Not in investable universe. Analyst target $18.64 (+114.8%), stop $8.07 (−7.6%), A.R:R 7.7:1. Score 5.3/10, moderate confidence.

What is the CTNM stock price target?

Analyst target: $18.64 (+114.8% upside). Analyst target $18.64 (+114.8%), stop $8.07 (−7.6%), A.R:R 7.7:1. Stop-loss: $8.07.

What are the risks of investing in CTNM?

Concentration risk — Pipeline: PIPE-791; Market cap $341M below $400M minimum; Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -5577.0%), Negative free cash flow.

Is CTNM overvalued or undervalued?

Contineum Therapeutics, Inc. trades at a P/E of N/A (forward -4.1). TrendMatrix value score: 9.0/10. Verdict: Hold.

What do analysts say about CTNM?

14 analysts rate CTNM, with a consensus score of 4.1/5. 7 analysts publish price targets averaging $21.

What does Contineum Therapeutics, Inc. do?Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for...

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis. Its partnered candidate PIPE-307, licensed to Johnson & Johnson as JNJ-89495120, missed the primary and secondary efficacy endpoints of a November 2025 Phase 2 trial in relapsing-remitting multiple sclerosis, though J&J continues a separate Phase 2 trial of the drug in major depressive disorder.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › CTNM

Latest news

Latest News

Fiscal.ai13d agoProduct
Fiscal.ai17d ago
Fiscal.ai19d ago
Benzinga19d ago
Benzinga19d ago
Fiscal.ai23d ago
Benzinga38d ago
Benzinga39d ago
Benzinga39d ago
Benzinga41d ago
Benzinga41d ago
Benzinga41d ago
Benzinga53d ago
Benzinga55d agoAnalyst
Benzinga68d agoProduct
Benzinga68d ago
Benzinga101d ago
Benzinga114d ago
Benzinga115d agoRestructuring
Benzinga115d ago
Loading more...